Phase 3 Clinical Trials With Primary Completion Dates in November 2024
This is a list of Phase 3 trials with primary completion dates in November 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
---|---|---|---|---|---|
IVVD | Invivyd, Inc. | 2024-11-01 | Phase 3 | NCT06039449 | A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 |